Done sou Salè H1B

Akèy › Anplwayè › Marksans Pharma Inc.

Marksans Pharma Inc.: Salè H-1B ak pajon

Marksans Pharma Inc. depoze 6 aplikasyon kondisyon travay pou visa H-1B ak visa ki gen rapò nan ane fiskal 2023–2026; sètifye: 4. Medyèn salè yo ofri a: $122,408.

Demann (LCA)6
Certifye4
Adrès anplwayèFarmingdale, NY
Anplwayè H-1B depannNon
Salè medyan ofri$122,408
Mwatye salè yo$116,402–$141,806
10yèm–90yèm pousantaj$105,591–$176,722

Èske Marksans Pharma Inc. pajone visa H-1B?

Marksans Pharma Inc. depoze 6 aplikasyon kondisyon travay nan ane fiskal 2023–2026, dènye a soumèt sou Aug 29, 2025. Yon LCA se premye etap yon demann H-1B, konsa anplwayè a pajone oswa prepare pou pajone travayè H-1B; li pa garanti pajon pou okenn travay espesifik. Tcheke lis travay pwòp anplwayè a.

Salè pa tit travay

Tit travayLCASalè medyan
Senior R&D Lead5$122,408
Vice President, Marketing1$200,000

Aplikasyon pa ane fiskal

Ane fiskalLCASalè medyan
FY20256$122,408

Nivo salè prevanlan

Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.

Kote travay yo ye

Okipasyon

Dènye aplikasyon yo

Tit travaySalè bazKoteSoumètDat kòmansmanEstati
Vice President, Marketing$200,000
E-3 · Nivo II
Brooklyn, NYAug 29, 2025Sep 29, 2025Certifye
Senior R&D Lead$98,384
Nivo I
New York, NYAug 25, 2025Sep 1, 2025Certifye
Senior R&D Lead$122,408
Nivo I
New York, NYJul 25, 2025Aug 11, 2025Certifye
Senior R&D Lead$98,384
Nivo I
New York, NYJul 25, 2025Aug 11, 2025Retire
Senior R&D Lead$122,408
Nivo I
New York, NYApr 10, 2025Apr 25, 2025Certifye
Senior R&D Lead$122,408
Nivo I
New York, NYApr 10, 2025Apr 25, 2025Retire

Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).